Combination Therapy of Rosuvastatin and Ezetimibe in Patients with High Cardiovascular Risk

Yang, Yoon Jung; Lee, Sang Hak; Kim, Byung Soo; Cho, Hyun Jai; Cho, Kyoung Im; Kim, Seok Yeon; Ryu, Jae Kean; Cho, Jin Man; Park, Joong Il; Park, Jong Seon; Park, Chang Gyu; Chun, Woo Jung; Kim, Myung A.; Jin, Dong Kyu; Lee, Nam-Ho; Kim, Byung Jin; Koh, Kwang Kon; Suh, Jon; Lee, Seung Hwan; Lee, Byoung Kwon; Oh, Seung Jin; Jin, Han; Ahn, Youngkeun; Lee, Sang Gon; Bae, Jang Ho; Park, Woo Jung; Lee, Sang‐Chol; Lee, Han Cheol; Lee, Jaewon; Park, Cheolwon; Lee, Backhwan; Jang, Yangsoo

doi:10.1016/j.clinthera.2016.11.014

Cited by 37 publications

(32 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Volume 40 Number 2 which was consistent with previous studies. [28][29][30] Another study also found greater LDL-C-lowering efficacy and similar safety profiles of rosuvastatin 5 or 10 mg combined with ezetimibe than those of rosuvastatin 10 or 20 mg monotherapy. 31 In previous research, administration of ezetimibe and rosuvastatin increased the target LDL-C goal from 67% to 96%.…”

Section: Clinical Therapeutics 238mentioning

confidence: 83%

A Phase III, Multicenter, Randomized, Double-blind, Active Comparator Clinical Trial to Compare the Efficacy and Safety of Combination Therapy With Ezetimibe and Rosuvastatin Versus Rosuvastatin Monotherapy in Patients With Hypercholesterolemia: I-ROSETTE (Ildong Rosuvastatin & Ezetimibe for Hypercholesterolemia) Randomized Controlled Trial

Hong

Jeong

Ahn

et al. 2018

Clinical Therapeutics

Self Cite

View full text Add to dashboard Cite

Fixed-dose combinations of ezetimibe/rosuvastatin significantly improved lipid profiles in patients with hypercholesterolemia compared with rosuvastatin monotherapy. All groups treated with rosuvastatin and ezetimibe reported a decrease in mean LDL-C level >50%. The safety and tolerability of ezetimibe/rosuvastatin therapy were comparable with those of rosuvastatin monotherapy. ClinicalTrials.gov identifier: NCT02749994.

show abstract

Section: Clinical Therapeutics 238mentioning

confidence: 83%

A Phase III, Multicenter, Randomized, Double-blind, Active Comparator Clinical Trial to Compare the Efficacy and Safety of Combination Therapy With Ezetimibe and Rosuvastatin Versus Rosuvastatin Monotherapy in Patients With Hypercholesterolemia: I-ROSETTE (Ildong Rosuvastatin & Ezetimibe for Hypercholesterolemia) Randomized Controlled Trial

Hong

Jeong

Ahn

et al. 2018

Clinical Therapeutics

Self Cite

View full text Add to dashboard Cite

show abstract

“…3). Rosuvastatin plus ezetimibe, an association of lipid lowering drugs used to treat patients with high cardiovascular risk, 33 and dapagliflozin plus metformin, 34 an association of antidiabetic agent, present very similar sales' patterns ( Fig. 3).…”

Section: Insights From the Six Pharmaceutical Substancesmentioning

confidence: 99%

Time-trend analysis of medicine sales and shortages during COVID-19 outbreak: Data from community pharmacies

Romano

Galante

Figueira

et al. 2021

Research in Social and Administrative Pharmacy

View full text Add to dashboard Cite

Background: COVID-19 is a worldwide public health concern. Disruptions in the drug market are expected and shortages might worsen. Community pharmacies can contribute to early identification and report of medicines' supply and demand issues. Objective: The aim of this study is to characterize the impact of the COVID-19 outbreak on outpatient medicines' sales and shortages. Methods: A retrospective, time-trend analysis of medicine sales, shortages and laboratory-confirmed COVID-19 cases was performed from February 1st to April 30th, 2020, and its homologous period (regarding sales only). A detailed analysis of 6 pharmaceutical substances was performed. All data were subjected to rescaling using the min-max normalization method, in order to become comparable. Data analysis was performed using Microsoft® Excel. Results: The pandemic resulted in an increase in medicines' demand and reported shortages during the early stage of the outbreak. The maximum proportion of medicine sales was registered on March 13th, 2020, 4 days after the WHO declared COVID-19 a pandemic. By the end of March, sales have already dropped to proportions similar to those of 2019. The maximum proportion of drug shortages was reached about one week after the sales peak and by the end of the study period were below those recorded in the pre-COVID-19 period. The analyzed drugs were paracetamol, ascorbic acid, dapagliflozin plus metformin, rosuvastatin plus ezetimibe, formoterol, and hydroxychloroquine, as these pharmaceutical substances registered the highest growth rate in sales and shortages when compared to the same period in the previous year. Hydroxychloroquine showed the most different pattern trends on sales and shortages of these medicines. Conclusions: Pharmacies can provide timely and real-world data regarding sales and shortages. The adopted measures to guarantee the continuous supply of the medicine market seem to have worked. The long-term impacts of this pandemic are unknown and should continue to be closely monitored.

show abstract

“…However, not all patients respond sufficiently to these treatments. 3 In such patients, treatment instead consists of a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor. 4 PCSK9 is an enzyme that plays an important role in lipid metabolism by modulating the density of LDL-C receptors in multiple organs.…”

mentioning

confidence: 99%

Cost-Effectiveness of PCSK9 Inhibitor Plus Statin in Patients With Triple-Vessel Coronary Artery Disease in Japan

Kodera

Morita

Kiyosue

et al. 2018

Circ J

View full text Add to dashboard Cite

Background: The addition of a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor to statin therapy reduces the rate of cardiovascular events. This study examined the cost-effectiveness of PCSK9 inhibitor+statin compared with standard therapy (statin monotherapy) in the treatment of triple-vessel coronary artery disease (CAD) in Japan. Methods and Results:A Markov model was applied to assess the costs and benefits associated with PCSK9 inhibitor+statin over a projected 30-year period from the perspective of a public healthcare payer in Japan. The incremental cost-effectiveness ratio (ICER), expressed as the quality-adjusted life-years (QALYs), was estimated. The effects on survival and numbers of events were based on the FOURIER trial and the CREDO Kyoto registry. The ICER of PCSK9 inhibitor+statin over standard therapy was 13.5 million (95% confidence interval 7.6-23.5 million) Japanese Yen (JPY) per QALY gained for triple-vessel CAD. The probability of the cost-effectiveness of PCSK9 inhibitor+statin vs. standard therapy was 0.0008% at a cost-effectiveness threshold of 5 million JPY. In patients with poorly controlled familial hypercholesterolemia (FH) with triple-vessel CAD, the ICER was 3.4 million JPY per QALY gained.Conclusions: PCSK9 inhibitor plus statin did not show good cost-effectiveness for triple-vessel CAD; however, it showed good cost-effectiveness for patients with triple-vessel CAD and poorly controlled FH in Japan.

show abstract

Combination Therapy of Rosuvastatin and Ezetimibe in Patients with High Cardiovascular Risk

Cited by 37 publications

References 21 publications

Time-trend analysis of medicine sales and shortages during COVID-19 outbreak: Data from community pharmacies

Cost-Effectiveness of PCSK9 Inhibitor Plus Statin in Patients With Triple-Vessel Coronary Artery Disease in Japan

Contact Info

Product

Resources

About